OncologyTube Professional - Patients Click Here
207,337 video views
Loading........
Description: Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestinal Cancers Symposium is Dr. Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assis...
01:33
Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestina​l Cancers Symposium is Dr. Richard Kim, MD, Gastrointestina​l Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, describes the different...
by:obr | 184 views
00:48
Dr. Khaldoun Almhanna, MD, MPH, Department of Gastrointestina​l Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, talks about the current state of gastroesophagea​l cancer screening and describes it’s use within the United States, here at the 2018 G...
by:obr | 114 views
01:07
The AJCC guidelines have incorporated several new features, Kenneth Wang, MD, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterolog​y and Hematology, explains these several new features like the separation on early stage cancer and a new criteria ...
by:obr | 121 views
01:33
Stivarga (regorafenib) is an effective drug but not one that is easily tolerable. Howard Hochster, MD, talks to us about the ReDOS study and its outcomes at the 2018 Gastrointestina​l Cancers Symposium.
by:obr | 169 views
01:07
At the 2018 Gastrointestina​l Cancers Symposium, David Ilson, MD, PhD, from the Memorial Sloan Kettering Cancer Center talks about a different number of strategies to individualize treatment and about the recently completed HER2 Trial.
by:obr | 100 views
00:56
The common discussion of where to start a patients dosage of regorafenib. Steven J. Cohen, MD, the Chief of the Medical Oncology and Hematology Division at Jefferson Health/Abington Hospital and Vice-Chair of the Department of Medical Oncology at Sidney Kimmel Cancer Center at Thomas Jefferson Unive...
by:obr | 161 views
01:02
Determining the progression and the responses of Hepatocellular Carcinoma (HCC). Professor Andrew X. Zhu, MD, PhD from Harvard Medical School and also the Director of Liver Cancer Research, comes to use from the 2018 Gastrointestina​l Cancers Symposium to talk about the ways we diagnose and assess th...
by:obr | 47 views
01:53
The choice of first line therapy differs on tumor sidedness. Professor Alan P. Venook, MD, joins us from the 2018 Gastrointestina​l Cancers Symposium and talks about the deciding factor when it comes to the first line of therapy for either left-sided or right-sided patients.
by:obr | 34 views
02:48
Jack West, MD of Swedish Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being incorporated into lung cancer treatment algorithms at the 2017 ASCO Annual Meeting in Chicago, IL.
by:obr | 947 views
01:12
Jack West, MD of Swedish Cancer Institute discusses the use of IDO inhibitors for the treatment of lung cancer patients at the 2017 ASCO Annual Meeting in Chicago, IL.
by:obr | 468 views

About obr
Description: OBR is the most comprehensive digital platform for oncology focused news and information: We aggregate, customize and prioritize daily oncology news and publications (OBR Daily for industry and providers, RSS newsfeeds) We research, develop and publish original content (OBR green) We create and produce customized training programs for pharmaceutical professionals (Oncology Business Dynamics) We conduct, interpret, analyze and produce original research (On-Telligence) We publish informational resources and editorial perspective to our websites (OBR Radar, Pipeline Online, Blog, Twitter, OBR Finance, News Pulse, KOL Commentary, and others)

Links
Channel Url:

Website:


Social Links: